Comprehensive Analysis of TSPAN11: A Potential Prognostic and Immunotherapy Biomarker in Colorectal Cancer.

IF 3.3 4区医学 Q3 CHEMISTRY, MEDICINAL

Current topics in medicinal chemistry Pub Date : 2025-08-06 DOI:10.2174/0115680266392910250728013705

Pengjun Sun, Dongbing Li, Jiajia Yan

{"title":"Comprehensive Analysis of TSPAN11: A Potential Prognostic and Immunotherapy Biomarker in Colorectal Cancer.","authors":"Pengjun Sun, Dongbing Li, Jiajia Yan","doi":"10.2174/0115680266392910250728013705","DOIUrl":null,"url":null,"abstract":"Introduction: Colorectal cancer (CRC) remains a significant global health challenge due to its high incidence and mortality rates. The disease's complexity and heterogeneity impede early diagnosis and effective treatment. The study aims to investigate the role of Tetraspanin 11 (TSPAN11) in CRC, exploring its potential as a prognostic biomarker and immunotherapy target through bioinformatics analysis and experimental validation.Methods: Pan-cancer patient data were obtained from The Cancer Genome Atlas (TCGA) and the GSE71187 dataset, including 672 CRC tissues and 51 adjacent normal tissues. Differential expression analysis, Kaplan-Meier survival analysis, gene set enrichment analysis (GSEA), and immune infiltration assessment were performed. TSPAN11 expression was validated in CRC cell lines using quantitative reverse transcription PCR (qRT-PCR).Results: TSPAN11 was significantly downregulated in CRC tissues compared to normal tissues (p < 0.001), with lower expression associated with poorer overall survival (OS; p = 0.011) and disease- specific survival (DSS; p = 0.038). Multivariate analysis identified TSPAN11 as an independent prognostic factor (p = 0.045). TSPAN11 expression was linked to key pathways such as ECM receptor interaction and TGF-β signaling, and correlated with immune infiltration, immune checkpoint genes, tumor mutational burden (TMB), microsatellite instability (MSI), and drug sensitivity.Discussion: The findings suggest that TSPAN11 may influence CRC progression through multiple biological pathways and immune-related mechanisms. Its downregulation is associated with poorer prognosis and immune evasion, highlighting its potential as a biomarker and therapeutic target. However, validation in larger cohorts and elucidation of underlying mechanisms are needed to confirm these results and translate them into clinical practice.Conclusion: TSPAN11 may serve as a promising prognostic biomarker and immunotherapy target in CRC. Its associations with clinical outcomes, immune features, and drug sensitivity underscore its potential for improving CRC diagnosis and treatment strategies.","PeriodicalId":11076,"journal":{"name":"Current topics in medicinal chemistry","volume":" ","pages":""},"PeriodicalIF":3.3000,"publicationDate":"2025-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current topics in medicinal chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0115680266392910250728013705","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Colorectal cancer (CRC) remains a significant global health challenge due to its high incidence and mortality rates. The disease's complexity and heterogeneity impede early diagnosis and effective treatment. The study aims to investigate the role of Tetraspanin 11 (TSPAN11) in CRC, exploring its potential as a prognostic biomarker and immunotherapy target through bioinformatics analysis and experimental validation.

Methods: Pan-cancer patient data were obtained from The Cancer Genome Atlas (TCGA) and the GSE71187 dataset, including 672 CRC tissues and 51 adjacent normal tissues. Differential expression analysis, Kaplan-Meier survival analysis, gene set enrichment analysis (GSEA), and immune infiltration assessment were performed. TSPAN11 expression was validated in CRC cell lines using quantitative reverse transcription PCR (qRT-PCR).

Results: TSPAN11 was significantly downregulated in CRC tissues compared to normal tissues (p < 0.001), with lower expression associated with poorer overall survival (OS; p = 0.011) and disease- specific survival (DSS; p = 0.038). Multivariate analysis identified TSPAN11 as an independent prognostic factor (p = 0.045). TSPAN11 expression was linked to key pathways such as ECM receptor interaction and TGF-β signaling, and correlated with immune infiltration, immune checkpoint genes, tumor mutational burden (TMB), microsatellite instability (MSI), and drug sensitivity.

Discussion: The findings suggest that TSPAN11 may influence CRC progression through multiple biological pathways and immune-related mechanisms. Its downregulation is associated with poorer prognosis and immune evasion, highlighting its potential as a biomarker and therapeutic target. However, validation in larger cohorts and elucidation of underlying mechanisms are needed to confirm these results and translate them into clinical practice.

Conclusion: TSPAN11 may serve as a promising prognostic biomarker and immunotherapy target in CRC. Its associations with clinical outcomes, immune features, and drug sensitivity underscore its potential for improving CRC diagnosis and treatment strategies.

查看原文本刊更多论文

TSPAN11的综合分析：结直肠癌的潜在预后和免疫治疗生物标志物。

导语：结直肠癌（CRC）由于其高发病率和死亡率仍然是一个重大的全球健康挑战。该病的复杂性和异质性阻碍了早期诊断和有效治疗。本研究旨在探讨Tetraspanin 11 （TSPAN11）在结直肠癌中的作用，通过生物信息学分析和实验验证，探索其作为预后生物标志物和免疫治疗靶点的潜力。方法：从癌症基因组图谱（TCGA）和GSE71187数据集中获取泛癌患者数据，包括672例结直肠癌组织和51例邻近正常组织。进行差异表达分析、Kaplan-Meier生存分析、基因集富集分析（GSEA）和免疫浸润评估。利用定量反转录PCR （qRT-PCR）验证了TSPAN11在结直肠癌细胞系中的表达。结果：与正常组织相比，TSPAN11在结直肠癌组织中显著下调（p < 0.001），低表达与较差的总生存期相关(OS；p = 0.011)和疾病特异性生存率(DSS；P = 0.038)。多因素分析发现TSPAN11是一个独立的预后因素（p = 0.045）。TSPAN11的表达与ECM受体相互作用和TGF-β信号传导等关键通路有关，并与免疫浸润、免疫检查点基因、肿瘤突变负担（TMB）、微卫星不稳定性（MSI）和药物敏感性相关。讨论：研究结果表明，TSPAN11可能通过多种生物学途径和免疫相关机制影响结直肠癌的进展。其下调与预后不良和免疫逃避有关，突出了其作为生物标志物和治疗靶点的潜力。然而，需要在更大的队列中进行验证，并阐明潜在的机制，以确认这些结果并将其转化为临床实践。结论：TSPAN11可作为结直肠癌的预后生物标志物和免疫治疗靶点。它与临床结果、免疫特征和药物敏感性的关联强调了其改善CRC诊断和治疗策略的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current topics in medicinal chemistry 医学-医药化学

CiteScore

6.40

自引率

2.90%

发文量

186

审稿时长

3-8 weeks

期刊介绍： Current Topics in Medicinal Chemistry is a forum for the review of areas of keen and topical interest to medicinal chemists and others in the allied disciplines. Each issue is solely devoted to a specific topic, containing six to nine reviews, which provide the reader a comprehensive survey of that area. A Guest Editor who is an expert in the topic under review, will assemble each issue. The scope of Current Topics in Medicinal Chemistry will cover all areas of medicinal chemistry, including current developments in rational drug design, synthetic chemistry, bioorganic chemistry, high-throughput screening, combinatorial chemistry, compound diversity measurements, drug absorption, drug distribution, metabolism, new and emerging drug targets, natural products, pharmacogenomics, and structure-activity relationships. Medicinal chemistry is a rapidly maturing discipline. The study of how structure and function are related is absolutely essential to understanding the molecular basis of life. Current Topics in Medicinal Chemistry aims to contribute to the growth of scientific knowledge and insight, and facilitate the discovery and development of new therapeutic agents to treat debilitating human disorders. The journal is essential for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important advances.